[ad_1]
 |
|
▲ A clinical substance is being produced for the treatment of the Celltrion Corona 19 antibody. |
These clinical results were announced by Celltrion at the ‘Korean Society for Infectious Diseases and Korean Antimicrobial Therapy Fall 2020 Conference’, held online from Day 5. The presentation at the conference was delivered via an oral presentation. by Kim Jin-yong, an infectious medicine specialist at Incheon Medical Center, who participated in the CT-P59 clinical trial.
This clinical trial evaluated the safety and tolerability of CT-P59, changes in clinical symptoms, and viral changes in 18 mild early-stage Corona 19 patients in three clinical trials in Korea and Europe.
As a result, no specific abnormal cases were observed due to the administration of CT-P59, confirming the safety and tolerability, and it was confirmed that the average time needed to recover from symptoms after administration of the drug was reduced by 44%. compared to the placebo group. All patients who received CT-P59 recovered, but some of the placebo groups worsened. Most of the participants in this clinical trial were elderly and, unlike the placebo group, none of the patients who received CT-P59 developed serious disease.
In particular, as a result of the administration of the drug to patients with high initial virus concentration, the virus decreased more rapidly than the placebo group, confirming the effect of early treatment through the antiviral effect of CT-P59.
Jin-yong Kim, an infectious medicine specialist at Incheon Medical Center, said: “We were able to confirm that symptoms were actually alleviated when CT-P59 was administered to mild patients in the early stages of Corona 19. We hope that the effect of CT-P59 can be demonstrated in a large-scale clinical trial currently underway. “He explained.
Celltrion plans to further accelerate the large-scale global clinical trial of CT-P59, a corona19 antibody treatment, through clinical outcomes. Celltrion is conducting clinical phases 2 and 3 globally in several countries, including Korea, and plans to secure interim results for these clinical trials later this year. It also aims to apply for global approval next year by conducting preventive clinical trials for close contacts.
Additionally, Celltrion has been producing validated process batches since last September to allow for immediate mass delivery as soon as drug development is complete.
A Celltrion official said: “Through this clinical outcome announced at the conference, we have confirmed the initial treatment effect of early administration of COVID-19 antibody treatment that the company has been emphasizing.” “Due to limitations, we will make every effort to provide CT-P59 early by accelerating the phase 2 clinical trials currently underway and obtaining results that meet the criteria.”
Reporter Lee Na-kyung [email protected]
